Financial Performance - The company reported a basic earnings per share of -0.4100 yuan for 2024, a decrease of 257.69% compared to 0.2600 yuan in 2023 [1] - The net profit for 2024 was -0.48 billion yuan, reflecting a significant decline of 260% from 0.3 billion yuan in 2023 [1] - The return on equity (ROE) dropped to -3.19% in 2024, down from 1.98% in 2023, indicating a decline of 261.11% [1] - Operating revenue increased to 10.32 billion yuan in 2024, a growth of 3.61% from 9.96 billion yuan in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 25.3355 million shares, accounting for 27.33% of the circulating shares, which is a decrease of 2.2876 million shares from the previous period [1] - The largest shareholder, 阮秀莲, holds 9.6839 million shares, representing 10.44% of the total share capital, with no change in holdings [2] - 江苏高投发展创业投资有限公司 reduced its holdings by 697.8 thousand shares, now holding 5.6176 million shares, which is 6.06% of the total [2] Dividend Policy - The company has announced no distribution or capital increase for the current period [1]
华绿生物:2024年报净利润-0.48亿 同比下降260%